BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19255091)

  • 1. Structural basis for the sequence-dependent effects of platinum-DNA adducts.
    Ramachandran S; Temple BR; Chaney SG; Dokholyan NV
    Nucleic Acids Res; 2009 May; 37(8):2434-48. PubMed ID: 19255091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of platinum-DNA adducts by HMGB1a.
    Ramachandran S; Temple B; Alexandrova AN; Chaney SG; Dokholyan NV
    Biochemistry; 2012 Sep; 51(38):7608-17. PubMed ID: 22950413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.
    Sharma S; Gong P; Temple B; Bhattacharyya D; Dokholyan NV; Chaney SG
    J Mol Biol; 2007 Nov; 373(5):1123-40. PubMed ID: 17900616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flanking bases influence the nature of DNA distortion by platinum 1,2-intrastrand (GG) cross-links.
    Bhattacharyya D; Ramachandran S; Sharma S; Pathmasiri W; King CL; Baskerville-Abraham I; Boysen G; Swenberg JA; Campbell SL; Dokholyan NV; Chaney SG
    PLoS One; 2011; 6(8):e23582. PubMed ID: 21853154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair protein.
    Elder RM; Jayaraman A
    Biophys J; 2012 May; 102(10):2331-8. PubMed ID: 22677386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein interactions with platinum-DNA adducts: from structure to function.
    Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
    J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link.
    Wu Y; Bhattacharyya D; King CL; Baskerville-Abraham I; Huh SH; Boysen G; Swenberg JA; Temple B; Campbell SL; Chaney SG
    Biochemistry; 2007 Jun; 46(22):6477-87. PubMed ID: 17497831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
    Chaney SG; Campbell SL; Bassett E; Wu Y
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase beta on templates with platinum-DNA adducts.
    Vaisman A; Warren MW; Chaney SG
    J Biol Chem; 2001 Jun; 276(22):18999-9005. PubMed ID: 11259423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
    Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
    Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unrestrained 5 ns molecular dynamics simulation of a cisplatin-DNA 1,2-GG adduct provides a rationale for the NMR features and reveals increased conformational flexibility at the platinum binding site.
    Elizondo-Riojas MA; Kozelka J
    J Mol Biol; 2001 Dec; 314(5):1227-43. PubMed ID: 11743736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translesion synthesis past platinum DNA adducts by human DNA polymerase mu.
    Havener JM; Nick McElhinny SA; Bassett E; Gauger M; Ramsden DA; Chaney SG
    Biochemistry; 2003 Feb; 42(6):1777-88. PubMed ID: 12578393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
    Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
    Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of carrier ligands of platinum(II) anticancer complexes in the protein recognition of Pt-DNA adducts.
    He Y; Yuan J; Qiao Y; Wang D; Chen W; Liu X; Chen H; Guo Z
    Chem Commun (Camb); 2015 Sep; 51(74):14064-7. PubMed ID: 26248639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex.
    Wu Y; Pradhan P; Havener J; Boysen G; Swenberg JA; Campbell SL; Chaney SG
    J Mol Biol; 2004 Aug; 341(5):1251-69. PubMed ID: 15321720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
    Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chiral differentiation of DNA adducts formed by enantiomeric analogues of antitumor cisplatin is sequence-dependent.
    Delalande O; Malina J; Brabec V; Kozelka J
    Biophys J; 2005 Jun; 88(6):4159-69. PubMed ID: 15805172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA adducts of the enantiomers of the Pt(II) complexes of the ahaz ligand (ahaz=3-aminohexahydroazepine) and recognition of these adducts by HMG domain proteins.
    Malina J; Vojtiskova M; Brabec V; Diakos CI; Hambley TW
    Biochem Biophys Res Commun; 2005 Jul; 332(4):1034-41. PubMed ID: 15922304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
    Malina J; Novakova O; Vojtiskova M; Natile G; Brabec V
    Biophys J; 2007 Dec; 93(11):3950-62. PubMed ID: 17704160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.